UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 390

Sortiert nach

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Journal of the neurological sciences, 2017-01, Vol.372, p.331-341

2017

Link zum Volltext

Verfügbarkeit prüfen

Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis

Neurology, 2015-02, Vol.84 (8), p.776

2015

Link zum Volltext

Verfügbarkeit prüfen

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

Human molecular genetics, 2009-06, Vol.18 (11), p.2078-2090

2009

Link zum Volltext

Verfügbarkeit prüfen

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1075-1084

2016

Link zum Volltext

Verfügbarkeit prüfen

Outcome Measures in Clinical Trials for Multiple Sclerosis

CNS drugs, 2017-03, Vol.31 (3), p.217-236

2017

Link zum Volltext

Verfügbarkeit prüfen

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study

Journal of neurology, 2016-07, Vol.263 (7), p.1323-1331

2016

Link zum Volltext

Verfügbarkeit prüfen

Gray matter damage in multiple sclerosis: Impact on clinical symptoms

Neuroscience, 2015-09, Vol.303, p.446-461

2015

Link zum Volltext

Verfügbarkeit prüfen

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Multiple sclerosis, 2020-12, Vol.26 (14), p.1816-1821

2020

Link zum Volltext

Verfügbarkeit prüfen

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment

Multiple sclerosis, 2020-01, Vol.26 (1), p.23-37

2020

Link zum Volltext

Verfügbarkeit prüfen

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

JAMA neurology, 2019-03, Vol.76 (3), p.274

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data

Neurology, 2019-11, Vol.93 (21), p.e1921

2019

Link zum Volltext

Verfügbarkeit prüfen

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Lancet neurology, 2012, Vol.11 (1), p.33-41

2012

Link zum Volltext

Verfügbarkeit prüfen

Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant

Brain (London, England : 1878), 2016-01, Vol.139 (Pt 1), p.115-126

2016

Link zum Volltext

Verfügbarkeit prüfen

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

PloS one, 2016-01, Vol.11 (1), p.e0143942-e0143942

2016

Link zum Volltext

Verfügbarkeit prüfen

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

CNS drugs, 2018-06, Vol.32 (6), p.543-558

Uitdehaag, Bernard M. J.

2018

Link zum Volltext

Verfügbarkeit prüfen

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

Brain (London, England : 1878), 2018-09, Vol.141 (9), p.2605-2618

2018

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

JAMA neurology, 2021-07, Vol.78 (7), p.880

2021

Link zum Volltext

Verfügbarkeit prüfen

Disruption of structural and functional networks in long-standing multiple sclerosis

Human brain mapping, 2014-12, Vol.35 (12), p.5946-5961

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

Multiple sclerosis, 2014-04, Vol.20 (4), p.481-488

2014

Link zum Volltext

Verfügbarkeit prüfen

Increased default-mode network centrality in cognitively impaired multiple sclerosis patients

Neurology, 2017-03, Vol.88 (10), p.952

2017

Link zum Volltext

Verfügbarkeit prüfen

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis

Neurology, 2017-05, Vol.88 (22), p.2107

2017

Link zum Volltext

Verfügbarkeit prüfen

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis

Neurology, 2019-10, Vol.93 (14), p.e1348

2019

Link zum Volltext

Verfügbarkeit prüfen

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis

Neurology, 2013-01, Vol.80 (1), p.69

2013

Link zum Volltext

Verfügbarkeit prüfen

Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions

Neurology, 2013-03, Vol.80 (11), p.1025

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 390

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(341)
Mit Volltextzugriff
(343)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Outcome Measures in Clinical Trials for Multiple Sclerosis

Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study

Gray matter damage in multiple sclerosis: Impact on clinical symptoms

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort

Disruption of structural and functional networks in long-standing multiple sclerosis

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

Increased default-mode network centrality in cognitively impaired multiple sclerosis patients

Increased connectivity of hub networks and cognitive impairment in multiple sclerosis

Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis

Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions

Suchergebnisse filtern